GMP IPO Watch
Mirae Asset Nifty 500 Healthcare ETF
Mirae Asset Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.66% | +4.12% | 60 of 85 |
| 1M | +3.50% | +3.71% | 41 of 81 |
| 3M | +0.54% | -3.27% | 5 of 71 |
| 6M | +13.18% | +1.12% | 1 of 63 |
| YTD | +18.24% | -1.76% | 1 of 85 |
| INCEPTION | +25.87% | — | — |
Ranked among: Exchange Traded Funds (ETFs) - Equity ETF.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +7.92% | +20.72% | -5.99% | 83% | 35% |
| 6M | +15.64% | +25.02% | +5.77% | 100% | 46% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.96%
- Debt0.00%
- Cash0.04%
- Other0.00%
Market Cap Split
- Large Cap35.99%
- Mid Cap45.65%
- Small Cap18.34%
- Others0.02%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 40.73 | — |
| P/B | 5.75 | — |
| Price / Sales | 5.93 | — |
| Price / Cash Flow | 30.74 | — |
| Dividend Yield (%) | 0.55 | — |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 10.13% | +0.23% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 8.76% | +0.23% |
| Apollo Hospitals | Equity | 6.24% | -0.26% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 5.72% | +0.44% |
| Cipla | Pharmaceuticals & Biotechnology | 5.62% | +0.00% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 5.58% | +0.59% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 5.24% | -0.03% |
| Max Healthcare Institute | Equity | 5.13% | -0.37% |
| Lupin | Pharmaceuticals & Biotechnology | 3.66% | -0.11% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 3.43% | +0.06% |
| Fortis Healthcare | Equity | 2.98% | -0.37% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.61% | -0.04% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 2.31% | +0.10% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.14% | +0.08% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.10% | +0.16% |
View all 46 holdings
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 1.98% | +0.04% |
| Biocon | Pharmaceuticals & Biotechnology | 1.91% | -0.17% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.71% | +0.08% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 1.56% | +0.13% |
| Krishna Institute of Medical Sciences | Equity | 1.48% | +0.09% |
| Aster DM Quality Care | Equity | 1.38% | -0.05% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 1.36% | -0.04% |
| Wockhardt | Pharmaceuticals & Biotechnology | 1.30% | +0.20% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 1.26% | +0.10% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.22% | +0.14% |
| Dr. Lal Path Labs | Equity | 1.15% | +0.08% |
| Abbott | Pharmaceuticals & Biotechnology | 1.04% | +0.10% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 0.95% | +0.00% |
| Granules | Pharmaceuticals & Biotechnology | 0.93% | +0.08% |
| Narayana Hrudayalaya | Equity | 0.92% | -0.01% |
| Global Health | Equity | 0.90% | +0.00% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 0.89% | +0.04% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.85% | -0.04% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 0.69% | +0.13% |
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.60% | +0.15% |
| Natco Pharma | Pharmaceuticals & Biotechnology | 0.55% | +0.01% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 0.54% | +0.01% |
| Vijaya Diagnostic Centre | Equity | 0.52% | -0.01% |
| Syngene International | Equity | 0.51% | -0.03% |
| Rainbow Childrens Medicare | Equity | 0.49% | -0.01% |
| Poly Medicure | Equity | 0.47% | -0.01% |
| Rubicon Research | Pharmaceuticals & Biotechnology | 0.43% | — |
| Caplin Point Laboratories | Pharmaceuticals & Biotechnology | 0.40% | +0.04% |
| Concord Biotech | Pharmaceuticals & Biotechnology | 0.34% | +0.00% |
| TREPS | Reverse Repo / TREPS | 0.13% | — |
| Net Receivables / (Payables) | Net Current Assets | -0.09% | — |
Sector Allocation · Sep 2026
Risk Metrics
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 3Y | 1.09 | -0.95 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Tracking Difference
Versus Nifty 500 Healthcare - TRI, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Aditya Birla Sun Life Silver ETF | +26.41% | +36.60% | — | +25.53% |
| Mirae Asset Nifty Metal ETF | +19.77% | — | — | +11.29% |
| Aditya Birla Sun Life Gold ETF | +17.03% | +31.14% | +23.34% | +11.72% |
| Aditya Birla Sun Life Nifty Healthcare ETF | +13.45% | +21.49% | +14.72% | +14.59% |
| Axis NIFTY Healthcare ETF | +13.26% | +21.08% | +14.40% | +13.81% |
| Mirae Asset S&P 500 Top 50 ETF | +8.91% | +26.13% | +16.80% | +18.42% |
|
Zerodha Nifty Smallcap 100 ETF
Direct Plan
|
+4.45% | — | — | +5.77% |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | +3.81% | — | — | +2.07% |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | +3.57% | — | — | +1.24% |
| Mirae Asset Nifty India Manufacturing ETF | +2.84% | +18.00% | — | +16.06% |
More From Mirae Asset Investment Managers (India) Pvt. Ltd
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Mirae Asset S&P 500 Top 50 ETF Fund of Fund
Direct Plan · Growth
|
+29.35% | +41.95% | +25.08% | +25.94% |
| Mirae Asset Silver ETF | +26.31% | +36.47% | — | +30.17% |
|
Mirae Asset NYSE FANG + ETF Fund of Fund
Direct Plan · Growth
|
+21.29% | +50.85% | +29.57% | +31.68% |
|
Mirae Asset Gold Silver Passive FoF
Direct Plan · IDCW
|
+21.29% | — | — | +35.40% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
| Mirae Asset Nifty Metal ETF | +19.77% | — | — | +11.29% |
|
Mirae Asset Global X Artificial Intelligence & Technology ETF Fund of Fund
Direct Plan · Growth
|
+18.59% | +34.76% | — | +33.45% |
| Mirae Asset Gold ETF | +16.94% | +31.04% | — | +27.13% |
|
Mirae Asset Gold ETF Fund of Fund
Direct Plan · Growth
|
+16.76% | — | — | +32.55% |
| Mirae Asset NYSE FANG+ ETF | +9.94% | +37.12% | +22.50% | +24.56% |
About This Scheme
Investment Objective
The investment objective of the scheme is to generate returns, before expenses, that are commensurate with the performance of the Nifty 500 Healthcare Total Return Index, subject to tracking error. There is no assurance that the investment objective of the scheme will be achieved.
Stated Asset Allocation
Securities included in Nifty 500 Healthcare Index- 95 to 100% ; Money market instruments* including Tri Party REPO/ debt securities, Instruments and/or units of debt/liquid schemes of domestic Mutual Funds- 0 to 5 %
Exit Load
NIL
Fund Managers
Mr. Vishal Singh & Mr. Sudip Shere
Ms. Ekta Gala (Primary) & Mr. Ritesh Patel (Primary)
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.